Japan · Delayed Price · Currency is JPY Olympus Earnings Call Transcripts
Fiscal Year 2026
-
Revenue guidance was revised down due to one-off ship holds and U.S. execution issues, but Q4 growth is expected. China is showing early signs of recovery, while FDA inspections and product holds continue to pose risks. Margin improvement targets remain unchanged.
-
Gradual revenue and margin growth are targeted, with a focus on innovation, restructuring, and disciplined capital allocation. New product launches and emerging market strategies underpin optimism, while restructuring and FDA remediation costs are being addressed.
-
Q1 FY2026 saw a 12% revenue decline and a 65% drop in adjusted operating profit, driven by tough comps, delayed purchases, and regulatory/tariff headwinds. Management expects recovery from Q2 with new product launches, cost control, and local production in China.
Fiscal Year 2025
-
FY2025 saw record revenue and strong profit growth, led by North America, despite China headwinds and supply chain disruptions. FY2026 guidance anticipates steady growth, increased R&D investment, higher dividends, and a major share buyback, with U.S. tariff risks being closely monitored.
-
Revenue grew 9% year-on-year, led by strong North American and SEA performance, but China’s ongoing challenges prompted a downward revision in full-year guidance. Adjusted operating profit and margins improved, with management targeting a return to 20%+ margins in the medium term.
-
Record-high revenue and double-digit growth in core segments were achieved in fiscal 2023, with operating margin reaching 20%. Fiscal 2024 guidance projects continued growth, increased dividends, and major investments in quality and innovation, amid ongoing regulatory and market challenges.
-
Q1 FY2025 saw 15% revenue growth and 21% higher operating profit, driven by strong North America performance and cost control. China remains a challenge, but guidance is unchanged, with robust U.S. growth and ongoing quality improvements supporting the outlook.